Rocket


News + Filings
Transactions





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other



Peterson Amy C. Create: Alert

All | News | Filings
Date FiledTypeDescription
08/25/2023 4 Peterson Amy C. (EVP Prod Dev & Med Aff & CMO) has filed a Form 4 on EXELIXIS, INC.
Txns: Granted 240,000 shares @ $0
Granted 160,000 options to buy @ $21.75, valued at $3.5M
08/25/2023 3 Peterson Amy C. (EVP Prod Dev & Med Aff & CMO) has filed a Form 3 on EXELIXIS, INC.
03/20/2023 4 Peterson Amy C. (EVP, Chief Development Officer) has filed a Form 4 on CytomX Therapeutics, Inc.
Txns: Sold 4,257 shares @ $1.979, valued at $8.4k
07/21/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
02/04/2022 4 Peterson Amy C. (EVP, Chief Development Officer) has filed a Form 4 on CytomX Therapeutics, Inc.
Txns: Granted 40,000 shares @ $0
Granted 200,000 options to buy @ $4.13, valued at $826k
10/26/2021 4 Peterson Amy C. (EVP, Chief Development Officer) has filed a Form 4 on CytomX Therapeutics, Inc.
Txns: Granted 50,000 options to buy @ $5.34, valued at $267k
Granted 40,000 options to buy @ $0
06/08/2021 4 Form 4 - Statement of changes in beneficial ownership of securities:
03/02/2021 4 Form 4 - Statement of changes in beneficial ownership of securities:
12/07/2020 4 Peterson Amy C. (EVP, Chief Development Officer) has filed a Form 4 on CytomX Therapeutics, Inc.
Txns: Granted 3,101 shares @ $6.392, valued at $19.8k
02/19/2020 4 Form 4 - Statement of changes in beneficial ownership of securities:
10/16/2019 4 Peterson Amy C. (EVP, Chief Development Officer) has filed a Form 4 on CytomX Therapeutics, Inc.
Txns: Granted 400,000 options to buy @ $7.16, valued at $2.9M
10/16/2019 3 Peterson Amy C. (EVP, Chief Development Officer) has filed a Form 3 on CytomX Therapeutics, Inc.
12/19/2018 4 Peterson Amy C. (CMO, Immuno-oncology) has filed a Form 4 on BeiGene, Ltd.
Txns: Exercised 9,859 shares @ $29.1, valued at $286.9k
Sold 900 shares @ $130.3678, valued at $117.3k
Sold 2,700 shares @ $131.7972, valued at $355.9k
Sold 1,700 shares @ $132.9137, valued at $226k
Sold 1,005 shares @ $133.8095, valued at $134.5k
Sold 778 shares @ $135.0446, valued at $105.1k
Sold 2,296 shares @ $136.2446, valued at $312.8k
Sold 480 shares @ $136.93, valued at $65.7k
Exercised 10,141 shares @ $29.1, valued at $295.1k
Sold 1,631 shares @ $131.735, valued at $214.9k
Sold 1,897 shares @ $132.7018, valued at $251.7k
11/13/2018 4 Peterson Amy C. (CMO, Immuno-oncology) has filed a Form 4 on BeiGene, Ltd.
Txns: Exercised 14,711 shares @ $29.1, valued at $428.1k
Sold 466 shares @ $122.8565, valued at $57.3k
Sold 2,423 shares @ $124.4759, valued at $301.6k
Sold 3,949 shares @ $126.0773, valued at $497.9k
Sold 7,673 shares @ $126.7197, valued at $972.3k
Sold 200 shares @ $127.6075, valued at $25.5k
Exercised 13,222 shares @ $29.1, valued at $384.8k
Sold 4,031 shares @ $118.635, valued at $478.2k
Sold 1,725 shares @ $119.2694, valued at $205.7k
Sold 2,100 shares @ $120.631, valued at $253.3k
Sold 2,898 shares @ $121.7059, valued at $352.7k
08/24/2018 4 Peterson Amy C. (CMO, Immuno-oncology) has filed a Form 4 on BeiGene, Ltd.
Txns: Sold 1,108 shares @ $167.536, valued at $185.6k
Sold 2,300 shares @ $168.9414, valued at $388.6k
Sold 1,400 shares @ $169.7543, valued at $237.7k
Sold 961 shares @ $170.4634, valued at $163.8k
06/28/2018 4 Peterson Amy C. (CMO, Immuno-oncology) has filed a Form 4 on BeiGene, Ltd.
Txns: Granted 44,564 shares @ $0
Granted 310,180 options to buy @ $0
11/15/2017 4 Peterson Amy C. (CMO, Immuno-oncology) has filed a Form 4 on BeiGene, Ltd.
Txns: Sold 2,400 shares @ $82.7887, valued at $198.7k
Sold 1,201 shares @ $83.3091, valued at $100.1k
08/24/2017 4 Form 4 - Statement of changes in beneficial ownership of securities:
06/29/2017 4 Form 4 - Statement of changes in beneficial ownership of securities
08/24/2016 4 Peterson Amy C. (CMO, Immuno-oncology) has filed a Form 4 on BeiGene, Ltd.
Txns: Granted 300,000 shares @ $0
Granted 1,600,000 options to buy @ $2.24, valued at $3.6M
08/24/2016 3 Peterson Amy C. (CMO, Immuno-oncology) has filed a Form 3 on BeiGene, Ltd.

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy